<DOC>
	<DOC>NCT02940925</DOC>
	<brief_summary>The purpose of this study is to compare the survival and toxicity of TPC (TAXOL, DDP AND CAPECITABINE ) VS PF (cisplatin and 5-Fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for stage IVa-b nasopharyngeal carcinoma patients in endemic area.</brief_summary>
	<brief_title>TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This is a prospective, parallel, randomized, open labeled, multicenter phase III clinical trial to compare the survival and toxicity of TPC VS PF as induction chemotherapy combined with CCRT for stage IVa-b nasopharyngeal carcinoma patients in endemic area.The primary endpoint is failure free survival (FFS）.The secondary endpoints are overall survival(OS）,progression-free survival（PFS）, local-regionally relapse free survival(LRFS), distant metastasis free survival（DMFS)and toxicities.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>WHO II or III pathological type stage Ⅳa or Ⅳb (UICC 7th edition) no anticancer treatment before no malignant history both gender, 1860 years old enough liver function: TBIL≤ULN；AST/ALT≤2.5×ULN；ALP≤5×ULN enough kidney function: Clcr≥80 mL/min enough hemo: ANC≥2×109/L, PLT≥100×109/L and HB≥9g/dL no sever heart, lung disfunction PS≤2 previous anticancer treatment distant metastasis pregnant or breasting female can not access to followup enrolled in other therapeutic clinical trial sever infection and internal disease sever disfunction of heart, lung, kidney, liver, etc TBIL&gt;ULN；AST/ALT&gt;2.5×ULN；ALP&gt;5×ULN with factors that will affect the administration, distribution,metabolism or evacuation. using immunosuppressive agents after organ transplantation other malignant history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>induction chemotherapy</keyword>
</DOC>